Mave® Tablet: Each film-coated tablet contains Mebeverine Hydrochloride BP 135 mg.
Mebeverine Hydrochloride (Mave®) is an effective antispasmodic agent used to treat irritable bowel syndrome and bowel spasm.
Mode of action:
Mebeverine Hydrochloride (Mave®) has direct relaxant effect on smooth muscle and thus reduces the spasm of the GI tract. It reduces the sodium ion permeability of smooth muscle cells. It also reduces potassium ion efflux, thus avoiding hypotonia.
Pharmacokinetics:
Mebeverine Hydrochloride (Mave®) is rapidly absorbed after oral administration with peak plasma concentrations occurring in 1 to 3 hours. It is 75% bound to albumin in plasma. The metabolites are excreted in the urine.
Symptomatic relief of irritable bowel syndrome and spasm of the gastro-intestinal tract.
Dosage & administrations:Adult and children over 10 years: 135-150 mg 3 times daily preferably 20 minutes before meals.
& administrations Adult and children over 10 years: 135-150 mg 3 times daily preferably 20 minutes before meals.
It should not be taken by pregnant woman unless the potential benefits outweigh the risk. Small amount is secreted in breast milk.
Mebeverine should be avoided in patients with paralytic ileus. Based on theoretical concerns, it should be used with care in patients with marked hepatic or renal impairment, and those with cardiac disorders such as heart block.
Overdosage:
In overdosage fatality takes place when thioridazine was taken. No specific antidote in case of CNS excitability.
Store in a cool and dry place, protected from light.